675109-30-5

Basic information

• Product Name: 1H-Isoindol-1-one, 2,3-dihydro-6-iodo-
• Synonyms: 1H-Isoindol-1-one, 2,3-dihydro-6-iodo-;6-Iodo-2,3-dihydro-1H-isoindol-1-one;6-iodo-2,3-dihydroisoindol-1-one
• CAS NO: 675109-30-5
• Molecular Formula: C8H6INO
• Molecular Weight: 259.04381
• Mol File: 675109-30-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1H-Isoindol-1-one, 2,3-dihydro-6-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindol-1-one, 2,3-dihydro-6-iodo-(675109-30-5)
• EPA Substance Registry System: 1H-Isoindol-1-one, 2,3-dihydro-6-iodo-(675109-30-5)

Safety Data

• Hazardous Substances Data: 675109-30-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Isoindol-1-one, 2,3-dihydro-6-iodois used as a key intermediate in the synthesis of various organic compounds. Its unique structure and functional groups make it a valuable precursor for the preparation of complex molecules with diverse applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-Isoindol-1-one, 2,3-dihydro-6-iodois utilized as a starting material for the development of potential drug candidates. Its chemical properties and structure enable the design and synthesis of novel molecules with therapeutic potential, particularly in the fields of medicinal chemistry and drug development.
Used in Medicinal Chemistry:
1H-Isoindol-1-one, 2,3-dihydro-6-iodois employed as a building block in medicinal chemistry for the synthesis of bioactive molecules. Its presence in the molecular structure can impart specific biological activities, making it a valuable component in the development of new drugs and therapeutic agents.
Used in Drug Development:
In the field of drug development, 1H-Isoindol-1-one, 2,3-dihydro-6-iodois studied for its potential biological activities and its role in the discovery of new pharmaceutical agents. Its unique structure and properties make it an attractive candidate for further research and development, with the aim of identifying and optimizing its therapeutic potential.

Upstream product

• 118-29-6 2-(hydroxymethyl)-1H-isoindole-1,3(2H)-dione 
• 618-51-9 3-Iodobenzoic acid 

Relevant articles and documents

NOVEL COMPOUNDS

The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as -NH-, with a cyclic group which in turn is substituted at the α-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

PYRIDINYL BASED APOPTOSIS SIGNAL-REGULATION KINASE INHIBITORS

Apoptosis signal-regulating kinase 1 (ASK1) activation and signaling have been reported to play an important role in a broad range of diseases including neurodegenerative, cardiovascular, inflammatory, autoimmunity and metabolic disorders. Disclosed herein is the synthesis of pyridinyl derived therapeutic agents that function as inhibitors of ASK 1 as well as their pharmaceutical compositions and methods of use.

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS

The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods fo

Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands

The present invention relates to compounds of formula I: in which R1 is a linear group or a five membered heterocycle optionally fused to a phenyl ring, R2 is a 5-membered heterocycle, R3 is chosen from a range of substituents, m is 0-3 and n is 0 or 1; the compounds are generally inverse agonists at GABA-A receptors containing the alpha 5 subunit and so are useful in methods of enhancing cognition in subjects with diminished cognition in diseases such as Alzheimer's Disease.